Yuanyuan Kong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3634026/publications.pdf

Version: 2024-02-01

623699 677123 44 640 14 22 citations g-index h-index papers 46 46 46 802 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatology International, 2022, 16, 1-23.	4.2	45
2	Clinical characteristics and genetics analysis for the ITD of congenital hypothyroidism. Journal of Pediatric Endocrinology and Metabolism, 2022, .	0.9	O
3	Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China. Journal of Clinical and Translational Hepatology, 2022, 10, 420-428.	1.4	5
4	A High Serum Level of Taurocholic Acid Is Correlated With the Severity and Resolution of Drug-induced Liver Injury. Clinical Gastroenterology and Hepatology, 2021, 19, 1009-1019.e11.	4.4	13
5	Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1423-1434.	2.8	45
6	Screening varices in patients with HBVâ€related cirrhosis on antiviral therapy: Platelet alone or together with LSM. Liver International, 2021, 41, 369-377.	3.9	4
7	Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clinical Gastroenterology and Hepatology, 2021, 19, 2499-2513.	4.4	26
8	Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatology International, 2021, 15, 611-620.	4.2	7
9	Novel Gross Deletion Mutations in NTRK1 Gene Associated With Congenital Insensitivity to Pain With Anhidrosis. Frontiers in Pediatrics, 2021, 9, 638190.	1.9	6
10	Blood transcriptome profiling as potential biomarkers of suboptimal health status: potential utility of novel biomarkers for predictive, preventive, and personalized medicine strategy. EPMA Journal, 2021, 12, 103-115.	6.1	18
11	Risk of Transmitting Coronavirus Disease 2019 During Nebulizer Treatment: A Systematic Review. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2021, 34, 155-170.	1.4	8
12	C4OH is a potential newborn screening marker—a multicenter retrospective study of patients with beta-ketothiolase deficiency in China. Orphanet Journal of Rare Diseases, 2021, 16, 224.	2.7	3
13	é⊷ä⅓性酪氷酸血症låž‹åŠå…¶ç›æŸ¥å'Œè⁻Šæ²»è¿›å±•. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of	f Zlæßang	Unoversity Me
14	Changing clinical care cascade of patients with chronic hepatitis B in Beijing, China. The Lancet Regional Health - Western Pacific, 2021, 16, 100249.	2.9	11
15	China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. Scandinavian Journal of Public Health, 2020, 48, 233-239.	2.3	4
16	Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatology International, 2020, 14, 105-114.	4.2	31
17	Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. Journal of Digestive Diseases, 2020, 21, 519-525.	1.5	11
18	Circular RNA circCTNNA1 promotes colorectal cancer progression by sponging miR-149-5p and regulating FOXM1 expression. Cell Death and Disease, 2020, 11, 557.	6.3	38

#	Article	IF	CITATIONS
19	High-Throughput Sequencing Reveals the Loss-of-Function Mutations in GALT Cause Recessive Classical Galactosemia. Frontiers in Pediatrics, 2020, 8, 443.	1.9	2
20	A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. OMICS A Journal of Integrative Biology, 2020, 24, 415-423.	2.0	9
21	Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clinical Gastroenterology and Hepatology, 2020, 18, 2582-2591.e6.	4.4	57
22	Clinical, biochemical and molecular spectrum of mild 6-pyruvoyl-tetrahydropterin synthase deficiency and a case report. Fetal and Pediatric Pathology, 2020, 40, 1-10.	0.7	3
23	Diagnosis of chronic stage of hypertensive retinopathy based on spectral domain optical coherence tomography. Journal of Clinical Hypertension, 2020, 22, 1247-1252.	2.0	4
24	Nonâ€obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cutâ€off to assess fibrosis stages. Journal of Digestive Diseases, 2020, 21, 279-286.	1.5	6
25	Noninvasive Evaluation of Liver Fibrosis Reverse Using Artificial Neural Network Model for Chronic Hepatitis B Patients. Computational and Mathematical Methods in Medicine, 2019, 2019, 1-8.	1.3	12
26	Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. Gastroenterology Research and Practice, 2019, 2019, 1-12.	1.5	16
27	A multimodal international collaborative clinical research training program in China. Medical Education Online, 2019, 24, 1679944.	2.6	1
28	Epidemiology and clinical course of primary biliary cholangitis in the Asia–Pacific region: a systematic review and meta-analysis. Hepatology International, 2019, 13, 788-799.	4.2	44
29	Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis. Hepatology International, 2019, 13, 766-776.	4.2	25
30	Impact of reimbursement program on liverâ€related mortality in patients with chronic hepatitis B in Beijing, China. Journal of Digestive Diseases, 2019, 20, 467-475.	1.5	6
31	Systematic review and metaâ€analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1676-1684.	2.8	46
32	Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. JAMA Oncology, 2019, 5, 915.	7.1	2
33	<p>Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study</p> . Infection and Drug Resistance, 2019, Volume 12, 745-757.	2.7	11
34	Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. Journal of Viral Hepatitis, 2019, 26, 576-585.	2.0	19
35	Prognosis of 732 ursodeoxycholic acidâ€treated patients with primary biliary cholangitis: A single center followâ€up study from China. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1236-1241.	2.8	15
36	Distribution-free models for latent mixed population responses in a longitudinal setting with missing data. Statistical Methods in Medical Research, 2019, 28, 3273-3285.	1.5	2

3

#	Article	IF	CITATIONS
37	Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. Journal of Clinical and Translational Hepatology, 2019, X, 1-7.	1.4	8
38	Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. International Journal of Infectious Diseases, 2018, 67, 58-64.	3.3	6
39	Onâ€treatment changes of liver stiffness at week 26 could predict 2â€year clinical outcomes in <scp>HBV</scp> â€related compensated cirrhosis. Liver International, 2018, 38, 1045-1054.	3.9	29
40	Early-life exposure to air pollutants and adverse pregnancy outcomes: protocol for a prospective cohort study in Beijing. BMJ Open, 2017, 7, e015895.	1.9	9
41	Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. Scientific Reports, 2016, 6, 37498.	3.3	13
42	Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense. Hepatology International, 2016, 10, 239-241.	4.2	2
43	A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis. International Journal of Environmental Research and Public Health, 2015, 12, 10039-10055.	2.6	16
44	Incorrect Calculation and Inappropriate Interpretation: Accuracy of International GuidelinesÂfor Identifying Significant Fibrosis inÂeÂAntigen–Negative Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2014, 12, 1407-1409.	4.4	1